Biotech entity
Every one of those 1 sits in a single category, pharma. Longeveron Inc. is most often covered alongside Kaltura, Inc., which appears in 1 of these 1 story. Each story carries 4 original sources on average, compared with 2.6 for the broader beat in this window.
Last mentioned: Mar 19, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Longeveron Inc. is most often covered alongside Kaltura, Inc., which appears in 1 of these 1 story. Each story carries 4 original sources on average, compared with 2.6 for the broader beat in this window. Their average consequence score of 5 runs below the beat's 6 for that window. Longeveron Inc. appears in 1 tracked Biotech story from March 19, 2026.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 23 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Longeveron Inc.. Shared-story counts are live from our verified record — not editorial picks.
Q4 2025 Earnings Call
Management discussed clinical progress of Lomecel-B and financial outlook.
Capital Raise
Entry into a material definitive agreement for the sale of unregistered equity securities.
NASDAQ Compliance Notice
Longeveron received notice of failure to satisfy NASDAQ listing rules.
Longeveron Inc. (LGVN) reported Q4 2025 results, highlighting clinical advancements in its Lomecel-B cell therapy for rare pediatric heart conditions and Alzheimer's disease. Despite clinical momentum, the company is managing significant financial headwinds, including a recent NASDAQ compliance notice and a subsequent capital raise in March 2026.
Longeveron Inc. is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
